兆科眼科-B(06622.HK) 公布,公司核心产品之一、用于治疗儿童近视加深的NVK002(低剂量阿托品0.01%)的简化新药申请已获中国国家药监局受理。此项申请以其在内地第III期临床试验结果为基础。(de/d)(港股报价延迟最少十五分钟。)
兆科眼科-B(06622.HK) 公布,公司核心产品之一、用于治疗儿童近视加深的NVK002(低剂量阿托品0.01%)的简化新药申请已获中国国家药监局受理。此项申请以其在内地第III期临床试验结果为基础。(de/d)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.